HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Zhou, H. Articles by Korth-Bradley, J. Search for Related Content PubMed PubMed Citation Articles by Zhou, H. Articles by Korth-Bradley, J. Social Bookmarking                   What's this?

Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin

From the Clinical Pharmacology Department, Wyeth Research, Collegeville, Pennsylvania (Dr Zhou, Ms Simcoe, Dr Korth-Bradley); Clinical Pharmacology Department, Wyeth Research, Paris, France (Ms Parks, Dr Patat); and Biotrial, Rennes, France (Dr Le Coz).

Etanercept, a soluble recombinant human tumor necrosis factor receptor (TNFr), is effective and well tolerated in the treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. The primary objective of this study was to investigate the potential pharmacokinetic and pharmacodynamic interaction between digoxin and etanercept at steady state. In a crossover, open-label, nonrandomized, 3-period study, 12 healthy male subjects received loading oral doses of digoxin 0.5 mg every 12 hours on day 1 and 0.25 mg every 12 hours on day 2, followed by a daily maintenance dose of 0.25 mg for a total of 27 days. Etanercept was administered as a twice-weekly 25-mg subcutaneous dose beginning on day 9 and continuing up to day 37 for a total of 9 doses. All ratios of maximum plasma concentration (C_max) and area under the plasma concentration versus time curve (AUC) for pharmacokinetics of digoxin fell within the confidence interval of 0.8 to 1.25. Although not considered clinically relevant, the mean C_max and AUC of etanercept were 4.2% and 12.5% lower, respectively, when etanercept was given with digoxin than when administered alone. There were no clinically relevant changes in the electrocardiogram (ECG) parameters, and adverse events did not increase when both drugs were combined. In conclusion, there is no clinically relevant interaction between etanercept and digoxin, and both drugs can be safely coadministered without the need for a dosage adjustment.

Key Words: Interaction • etanercept • digoxin

Address for reprints: Honghui Zhou, PhD, FCP, Clinical Pharmacology, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. Mahmood and M. D. Green Drug Interaction Studies of Therapeutic Proteins or Monoclonal Antibodies J. Clin. Pharmacol., December 1, 2007; 47(12): 1540 - 1554. [Abstract] [Full Text] [PDF]

				M. M. Hutmacher, I. Nestorov, T. Ludden, R. Zitnik, and C. Banfield Modeling the Exposure-Response Relationship of Etanercept in the Treatment of Patients With Chronic Moderate to Severe Plaque Psoriasis J. Clin. Pharmacol., February 1, 2007; 47(2): 238 - 248. [Abstract] [Full Text] [PDF]

				S. Kawai, H. Sekino, N. Yamashita, S. Tsuchiwata, H. Liu, and J. M. Korth-Bradley The comparability of etanercept pharmacokinetics in healthy Japanese and american subjects. J. Clin. Pharmacol., April 1, 2006; 46(4): 418 - 423. [Abstract] [Full Text] [PDF]

				H. Zhou Clinical Pharmacokinetics of Etanercept: A Fully Humanized Soluble Recombinant Tumor Necrosis Factor Receptor Fusion Protein J. Clin. Pharmacol., May 1, 2005; 45(5): 490 - 497. [Abstract] [Full Text] [PDF]

				H. Zhou, P. R. Mayer, J. Wajdula, and S. Fatenejad Unaltered Etanercept Pharmacokinetics With Concurrent Methotrexate in Patients With Rheumatoid Arthritis J. Clin. Pharmacol., November 1, 2004; 44(11): 1235 - 1243. [Abstract] [Full Text] [PDF]